Effects of dilazep on platelet functions and volume change in patients with diabetes mellitus.
Dilazep (CAS 35898-87-4), a vasodilating agent, was administered to patients with diabetes mellitus (300 mg/day for a minimum of two weeks). Various parameters of platelet function were evaluated both pre- and post-therapy. While dilazep affected neither aggregation nor intracellular Ca++ mobilization, it had a tendency to attenuate arachidonic acid metabolism induced by 0.1 U/ml thrombin (p = 0.1). The rate of platelet volume increase induced by weak acid loading was significantly higher post-therapy than pre-therapy. Since platelet volume change is generally suppressed in diabetic patients, dilazep administration appeared to normalize volume change induced by acid loading. It is implicated that dilazep reduced the membrane rigidity of platelets from diabetic patients, thereby allowing easy expansion of platelet volume.
Ozaki
Y
Y
Department of Clinical and Laboratory Medicine, Yamanashi Medical College, Japan.
Jinnai
Y
Y
Yatomi
Y
Y
Tawata
M
M
Onaya
T
T
Kume
S
S
D000368:Aged; D016718:Arachidonic Acid / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects*; D001810:Blood Volume / Q000187:drug effects*; D002118:Calcium / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood*; D004109:Dilazep / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010979:Platelet Function Tests; D000254:Sodium-Potassium-Exchanging ATPase / Q000097:blood
D016718:Arachidonic Acid; D000254:Sodium-Potassium-Exchanging ATPase; D004109:Dilazep; D002118:Calcium